Genetic immunotherapy is considered an ideal treatment modality for cancer because of its systemic nature. This study was designed to develop a potent novel genetic immunotherapy by combining conditionally replicating adenovirus (CRAd) and replication-defective adenovirus expressing interferon-b (ad-IFN-b). We investigated the efficacy of this therapy in an immunocompetent mouse tumor model. Transduction with CRAd (D24RGD) induced cytolysis in a mouse lung cancer cell line (Lewis lung carcinoma ( 
Introduction
Cancer remains a life-threatening illness in most cases. The current treatment modalities, such as surgery, chemotherapy and radiation, have limitations with regard to their effects on the improvement of cancer survival, including lung cancer. The need for new treatment modalities for patients with cancer has led to research in gene therapy, immunotherapy and new targeted therapies. Genetic immunotherapy has a great theoretical advantage over the current regimens; genetic immunotherapy is not destructive and cancer selective and uses the host's immune surveillance. However, many obstacles exist for the use of immunotherapy in the clinical setting, such as the absence of potent tumor-specific immune stimulants, the identification of ideal administration routes and the presence of defective host immune systems. 1 Recombinant adenoviruses expressing cytokines have been studied for a long time; however, to date, clinical trials with adenovirus (ad)-cytokine have shown only limited responses. [2] [3] [4] [5] The concept of an oncolytic adenovirus (conditionally replicating adenovirus (CRAd)) was introduced in 1996. A mutant adenovirus with a deletion of the E1B gene (ONYX-015) can replicate in and cause lysis of human cancer cells with defective p53, but not cells with intact p53. 6, 7 The D24 is another version of the CRAd with a 24-bp deletion in E1A; this adenovirus can replicate in cancer cells defective in the pRB/p16 pathway. Mutant E1 protein produced from D24 loses the potential of binding and inactivating pRb in normal cells that permits adenovirus to replicate; however, it can act as a normal E1 protein in cancer cells defective in the pRB/p16 pathway. 8 With the aim of improving antitumor effects, another modification of CRAd referred to as an armed therapeutic adenovirus has been introduced. 9 Several therapeutic genes, such as drug-sensitizing genes 10 and apoptosisinducing genes, 11 have been inserted into the E1 or E3 region of the CRAd. These viruses have dual antitumor effects (direct oncolysis due to tumor-specific replication and tumor-killing effects of the co-inserted therapeutic genes). An armed therapeutic adenovirus with therapeutic genes has been shown to improve the antitumor effects compared with the original CRAd; however, the antitumor effects previously reported are locoregional. 10, 11 Another version of an armed therapeutic adenovirus is the combination of oncolytic gene therapy and cytokine gene therapy. Cytokine genes have been inserted into CRAds. These adenoviruses were effectively replicated in and caused lysis of cancer cells, and also produced cytokines in the tumor microenvironment. Release of tumor antigens and the attraction of immune effector cells by high levels of cytokines have been shown to induce strong antitumor immunity. [12] [13] [14] [15] [16] Previously, we introduced a new strategy with combination gene therapy using the oncolytic adenovirus (D24) with E1-deleted, replication-defective adenovirus containing therapeutic genes instead of the oncolytic adenovirus containing the therapeutic genes. When both adenoviruses infected the same cancer cells, the mutant E1 protein from the D24 aided the E1-deleted adenovirus replicate in the cells (transcomplementation). As a result, both the D24 and E1-deleted adenoviruses replicated in and caused lysis of the cells, and spread laterally to the neighboring cancer cells. Furthermore, the tumor-restricted replication of the E1-deleted adenovirus induced a greater and more prolonged production of the therapeutic gene product with strong antitumor effects. 17, 18 In contrast to previous experiments, we used the murine lung cancer cell line for this experiment to evaluate antitumor immunity in syngeneic, immunocompetent mice. Can D24 with or without RGD engineered into the fiber knob protein efficiently infect murine cancer cells and induce the replication of cotransduced replication-defective adenovirus? This is an important issue to be answered in the experiments presented herein.
Interferon-b is known to stimulate antitumor immunity by regulating antibody production and activating natural killer, cytotoxic T lymphocytes (CTLs) and macrophage activity. 19, 20 Intrapulmonary instillation of adenovirusinterferon-b (ad-IFN-b) has been very effective in treating murine bronchogenic adenocarcinoma by direct killing due to natural killer cells and induction of CTL. 19, 21 This study was designed to evaluate a potent novel genetic immunotherapy with CRAd (D24RGD) and ad-IFN-b combined to induce tumor antigen release caused by CRAd and a greater and more prolonged production of IFN-b from tumor-restricted replication of ad-IFN-b.
Materials and methods

Recombinant adenoviruses
An adenovirus expressing mouse IFN-b was constructed using the BD Adeno-X expression system (BD Biosciences Clontech, Palo Alto, CA). Briefly, mouse IFN-b cDNA in pORF (InVivogen, San Diego, CA) was inserted into multiple cloning sites of the pShuttle 2. The mouse IFN-b was retrieved from the pShutte 2-IFN-b by digestion with I-CeuI and Pl-SceI, and then cloned into the BD adeno-X viral DNA by in vitro ligation. After digestion with Swa I and transformation into Escherichia coli, a large amount of adeno-X-IFN-b was obtained. Adeno-X-IFN-b was then transfected into 293 cells, and the generation of recombinant ad-IFN-b was confirmed by the appearance of the cytopathic effects. The ad-IFN-b was confirmed again by DNA sequencing of the cloning site. In addition, production of the mouse IFN-b was confirmed by enzyme-linked immunosorbent assay (ELI-SA) (mouse interferon-b ELISA kit; PBL Biomedical Laboratories, Piscataway, NJ).
The conditionally replicating adenovirus (CRAd), D24RGD, was provided by David T Curiel (University of Alabama at Birmingham). D24 and D24-luc (D24 containing the luciferase gene in the E3 region) were provided by Victor van Beusechem (VU University, the Netherlands). The D24RGD is a D24 with an Arg-GlyAsp (RGD) sequence in the adenoviral fibers, known to interact with a v -integrin to enhance tumor infection. 22 Adenovirus-luciferase (ad-luc) is a recombinant E1-deleted, replication-defective adenovirus with a CMVie promoter and luciferase gene in the E1 region of the adenoviral genome.
All the adenoviruses were propagated in the 293 cells and were concentrated and purified with the BD adeno-X purification kit (BD Biosciences Clontech). The titers of the adenoviruses were determined by the TCID 50 method.
Cells and animals
The mouse lung carcinoma cell line (Lewis lung carcinoma (LLC)) and A549 (human lung adenocarcinoma) were purchased from the American Type Culture Collection (Manassas, VA). Male C57BL/6 mice (6 weeks) were purchased from the Orient Corporation (Seongnam, Korea) and were originally from Charles River Laboratories International (Wilmington, MA).
Oncolysis of LLC by D24RGD
To confirm the replication and cytolysis of D24RGD in the mouse cancer cell line, LLC cells were transduced with ; the resulting spots were quantified using an image analyzer. 23 
Results
Cytolysis of LLC after transduction with D24RGD
We investigated whether D24RGD could infect, replicate and induce cytolysis in the mouse cancer cell line (LLC). Transduction with D24RGD induced cytolysis of LLC; however, it required a high dose of D24RGD. Cytolysis became evident at a D24RGD of 100 m.o.i. or more in the LLC. However, a D24RGD of 5 m.o.i. induced almost complete cytolysis in the human lung cancer cell line (A549) (Figure 1 ). We confirmed that D24RGD could infect and replicate in the mouse cancer cell line, even though it was more resistant to D24RGD than the human cancer cell line.
Mouse lung cancer (LLC) cells transduced with ad-luc and D24RGD expressed higher luciferase than cells transduced with ad-luc We confirmed that cotransduction with D24RGD and adluc induced a greater expression of luciferase in the mouse cancer cell line. Mouse lung cancer (LLC) cells and human lung cancer cells (A549) were transduced with adluc and D24RGD. In the LLC cells, the combined transduction of D24RGD (100 m.o.i.) and ad-luc (100 m.o.i.) resulted in a more than 50-fold increase in luciferase expression compared with ad-luc (100 m.o.i.) alone. In addition, combined transduction of D24RGD and ad-luc induced a slightly higher luciferase expression than the equivalent D24-luc. We confirmed the same outcome with the human lung cancer cell line (A549) at a lower adenovirus dose (10 m.o.i. each) (Figure 2) . Ad-luc (10)
Ad-luc (1) +Δ24 (10) Ad-luc (10) +Δ24 (10) Figure 6 ). However, we confirmed that the LLC cells transduced with ad-IFN-b and D24RGD maintained their tumor-forming potential. Therefore, all LLC cells used as tumor vaccines were treated with radiation (1 Gy) just before injection to reduce the tumorigenicity, but maintain the ability to produce cytokines.
Treatment potential of LLC transduced with ad-IFN-b and D24RGD
We evaluated the tumor vaccine strategy with the LLC transduced with adenovirus on established tumors. The mice treated with the tumor vaccines (LLC) transduced with ad-IFN-b alone or D24RGD alone showed no difference in survival compared with the untreated mice. However, the mice treated with LLC transduced with ad-IFN-b and D24RGD showed a modest increase in survival compared with the other groups (Po0.05, log-rank (Mantel-Cox); Figure 7 ). 
Enhanced cytotoxic T-cell response by cotransduction with D24RGD and ad-IFN-b
The results of the IFN-g ELISPOT assay revealed that the LLC-stimulated splenocytes from the mice treated with LLC-ad-IFN-b or LLC-D24RGD-ad-IFN-b showed higher immune cell generation than the splenocytes from mice treated with LLC-D24RGD. Furthermore, vaccination with LLC-D24RGD-ad-IFN-b induced a 73% increase in the IFN-g immune T-cell activation against LLC than the vaccination with LLC-ad-IFN-b (Figure 8 ). This finding suggests that enhanced cytotoxic T-cell activation by D24RGD þ ad-IFN-b might be the mechanism underlying the survival prolongation observed in the treatment experiment.
Discussion
Cancer is a systemic disease that is characterized by metastasis to multiple organs. Most cancer gene therapies, however, have focused on local treatment. This might be one of the reasons why gene therapy clinical trials have failed to produce significant results. Genetic immunotherapy might provide a method that solves these problems. Immunotherapy affects all cancer cells throughout the human body; thus, the impact is systemic. However, in spite of the initial expectations, many genetic immunotherapy protocols have also failed to show significant results in the clinical setting. 3, 4, [24] [25] [26] The absence or paucity of tumor antigens and inadequate immune stimuli might be, in part, the reasons for previous failures.
In this study, we focused on the release of tumor antigens by CRAd, and on the amount and duration of cytokines produced by the ad-cytokine and released into the tumor microenvironment to attract a variety of immune cells. These factors were predicted to facilitate the host immune system that would detect the tumor antigens and then generate a tumor-specific immune response against the tumor antigens resulting in the eradication of the tumors systemically. When we designed this study, we planned to use immune-competent mice and mouse cancer cell lines. However, most CRAds have been designed to infect and replicate in human cancer cells. This situation presented us with uncertainty that had to be addressed.
First, we had to determine whether the CRAd (D24RGD) could replicate in the mouse cancer cell line (LLC). Jogler et al. 27 reported that the CRAd could replicate only in porcine cells with efficiency close to that of human cells. The cells from all other species, including mice, were not permissive to the CRAd. 27 Thomas et al. 28 found that Syrian hamster cells were also permissive to the CRAd and suggested the Syrian hamster for the study of oncolytic adenoviral vectors. However, some mouse breast cancer cells were also permissive to the CRAd 29. In this study, mouse lung cancer cells (LLC) and human lung cancer cells (A549) were transduced with D24RGD at different concentrations and exhibited cell lysis. The LLC showed significant lysis with D24RGD over 100 m.o.i.; however, the A549 showed almost complete lysis at 5 m.o.i. (Figure 1 ). Therefore, these experiments confirmed that the D24RGD replicated and induced cell lysis in the LLC, even though it was more resistant and required higher concentrations of adenovirus than the human lung cancer cell line.
In addition, it was unclear whether cotransduction of the D24RGD and E1-deleted adenovirus in the mouse cancer cell line would induce the replication of E1-deleted adenovirus, as previously shown in human cancer cell lines. 17, 18 Theoretically, E1-deleted adenovirus could replicate with the aid of the mutant E1 protein produced by D24RGD in the pRB/p16 inactivated cells. However, we did not know whether this would occur in the mouse cancer cell line. Guo et al. 29 previously reported that D24 aided in the replication of ad-TRAIL in mouse breast cancer cells (4T1). Several experiments were carried out to investigate this question. The combined transduction of E1-deleted adenovirus containing the luciferase reporter gene (ad-luc) and D24RGD in the LLC produced a 50-fold increase in luciferase compared with the single transduction ( Figure 2 ). This finding strongly suggests that ad-luc can replicate in LLC with the aid of D24RGD. Finally, we investigated whether increased IFN-b production and cytolysis induced an immune response for tumor rejection. The injection of LLC-D24RGD-ad-IFN-b formed markedly smaller tumors than the LLC-D24RGD and LLC-ad-IFN-b; however, the tumorigenicity was not completely abolished. Therefore, we used irradiated LLC in the next treatment experiment to reduce the tumorigenicity, but maintain cytokine production. In most previous clinical trials using a tumor vaccine, the tumor cells were retrieved from the original tumor and genetically modified according to specific protocols. Finally, the cells were irradiated to abolish the tumorigenicity and injected into different sites. 4, 5, 30 Similarly, we designed treatment experiments to be carried out on established tumors, and injection of irradiated LLC-D24RGD-ad-IFN-b was used as a tumor vaccine and injected at different sites. The goal was to stimulate a systemic immune response. Treatment with the LLC-D24RGD-ad-IFN-b induced a modest, but significant increase in survival compared with LLC-D24RGD and LLC-ad-IFN-b. A more potent CTL response, measured by the IFN-g ELISPOT assay, was induced by LLC-D24RGD-ad-IFN-b than LLC-ad-IFN-b (Figure 8 ). This modest survival benefit was somewhat disappointing. These results could be explained by the unirradiated LLC-D24RGD-ad-IFN-b maintaining its tumorigenicity.
However, if we use this strategy with other potent immune cytokines, such as granulocyte macrophage colony-stimulating factor (GM-CSF) or interleukin (IL)-12, perhaps a stronger antitumor immune reaction would be found.
Our findings showed that the replicating potential of D24RGD in mouse cancer cells was very weak compared with its potential in human cells. If we applied this strategy to human cancer cells, we would expect more potent cell lysis leading to the release of tumor antigens, and a greater production of cytokines released into the tumor microenvironment. Many previous reports on oncolytic adenovirus carrying cytokine genes, such as GM-CSF, 15, 31 MDA-7/IL-24 13, 16, 32 and IL-12, 16 studied for genetic immunotherapy showed improved antitumor immunity by oncolysis and co-expressing cytokines. Some of the previous studies used human cancer cell lines in immunodeficient mice. 13, 32, 33 However, these findings are difficult to interpret because we could not expect the generation of adequate antitumor immune response in immunodeficient mice. Furthermore, oncolytic adenoviruses carrying cytokine genes have some limitations. For example, the insertion of cytokines into E3 reduced the replicating potential of CRAd. 34 In contrast to previous experiments, our study had three unique findings. First, we used two different adenoviruses, CRAd and the adenovirus with E1 replaced with cytokine cDNA instead of a single CRAd carrying cytokine gene. This combination induced tumor-restricted replication of the replication-defective ad-IFN-b. Second, we studied these vectors in immunocompetent animal models. Theoretically, any E1-deleted adenovirus expressing different cytokines or immune molecules, such as major histocompatibility complex molecules and immune costimulatory molecules (B7), could combine with CRAd. Furthermore, combination of multiple adenoviruses with CRAd is feasible. Finally, we chose to inject the vaccine at many different sites instead of the usual intratumoral injection; this was carried out to simulate the clinical situation of advanced cancer in patients with cancer spread throughout the body.
In conclusion, cotransduction of D24RGD and ad-IFN-b into the same cancer cells resulted in the replication-defective adenovirus (ad-IFN-b) replicating with the aid of mutant E1 produced by D24RGD; this resulted in release into the tumor microenvironment and the infection of adjacent tumor cells. A high local concentration of IFN-b and the local release of tumor antigens by CRAd induced strong antitumor immunity. Therefore, this combination strategy of ad-cytokines and CRAd might be useful for further study. Future experiments are planned to find the ideal combination for induction of the most potent antitumor immune response for the eradication of pre-existing tumors.
